Pegasus Asset Management Inc. boosted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 2.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,420 shares of the biopharmaceutical company’s stock after purchasing an additional 507 shares during the quarter. Pegasus Asset Management Inc.’s holdings in Bristol-Myers Squibb were worth $1,568,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of the business. Garrett Wealth Advisory Group LLC purchased a new stake in shares of Bristol-Myers Squibb during the 3rd quarter worth approximately $26,000. Lenox Wealth Advisors LLC grew its holdings in shares of Bristol-Myers Squibb by 555.7% in the third quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 539 shares in the last quarter. Financial Gravity Wealth Inc. grew its holdings in shares of Bristol-Myers Squibb by 101.2% in the third quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 327 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Bristol-Myers Squibb by 52.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 665 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 230 shares in the last quarter. Finally, Savior LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter worth $39,000. Institutional investors and hedge funds own 83.35% of the company’s stock.
BMY remained flat at $$67.43 during trading on Wednesday. The company had a trading volume of 15,186,480 shares, compared to its average volume of 10,912,332. The company has a current ratio of 3.83, a quick ratio of 3.72 and a debt-to-equity ratio of 1.37. The business’s 50 day moving average is $63.67 and its 200 day moving average is $53.66. The company has a market capitalization of $108.71 billion, a PE ratio of 19.43, a P/E/G ratio of 0.82 and a beta of 0.73. Bristol-Myers Squibb Co has a 12 month low of $42.48 and a 12 month high of $67.62.
The company also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be paid a dividend of $0.45 per share. The ex-dividend date of this dividend is Thursday, January 2nd. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. This represents a $1.80 dividend on an annualized basis and a dividend yield of 2.67%. Bristol-Myers Squibb’s payout ratio is currently 45.23%.
In related news, insider Louis S. Schmukler sold 25,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.56, for a total transaction of $1,414,000.00. Following the completion of the transaction, the insider now owns 31,963 shares in the company, valued at approximately $1,807,827.28. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP John E. Elicker sold 15,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $56.66, for a total value of $849,900.00. Following the transaction, the senior vice president now owns 74,471 shares of the company’s stock, valued at approximately $4,219,526.86. The disclosure for this sale can be found here. Corporate insiders own 0.13% of the company’s stock.
A number of research firms recently issued reports on BMY. Bank of America started coverage on shares of Bristol-Myers Squibb in a research note on Wednesday, October 16th. They set a “buy” rating and a $60.00 price target on the stock. Mizuho began coverage on shares of Bristol-Myers Squibb in a research note on Monday, November 25th. They issued a “buy” rating for the company. Morgan Stanley began coverage on shares of Bristol-Myers Squibb in a report on Friday, November 22nd. They issued an “equal weight” rating and a $60.00 target price on the stock. William Blair restated a “buy” rating on shares of Bristol-Myers Squibb in a report on Friday, December 13th. Finally, UBS Group upped their target price on shares of Bristol-Myers Squibb from $51.00 to $53.00 and gave the company a “neutral” rating in a research report on Wednesday, October 23rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $61.69.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Recommended Story: Is it Safe to Invest in Commodities?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.